Otonomy Announces Closing of Follow-on Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
January 28, 2015 16:02 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 28, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Announces Pricing of Follow-on Public Offering
January 22, 2015 20:34 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 22, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Announces Launch of Follow-on Public Offering
January 21, 2015 16:01 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Provides Corporate and Product Pipeline Update
January 08, 2015 16:55 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy to Present at the J.P. Morgan Healthcare Conference
January 06, 2015 08:00 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere's Disease
December 01, 2014 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy to Present at the Piper Jaffray Healthcare Conference
November 20, 2014 08:30 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 20, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Third Quarter 2014 Financial Results and Provides Corporate Update
November 12, 2014 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Obtains Rights to Gacyclidine Data From Ipsen to Support Development of OTO-311 as a Treatment for Tinnitus
November 06, 2014 01:00 ET
|
Otonomy, Inc.
SAN DIEGO and PARIS, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative...
Otonomy Appoints Anthony J. Yost Chief Commercial Officer
October 21, 2014 07:29 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 21, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...